LONDON: N4 Pharma plc (AIM: N4P), a UK-based biotechnology company developing its proprietary Nuvec® gene delivery system for advanced cancer and disease therapies, announced its audited financial results for the year ended Dec. 31, 2024. The company’s annual report and notice of its annual general meeting (AGM) have been distributed to shareholders. The AGM…